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ABSTRACT
Awake Fiberoptic Intubation (AFOI) is the gold standard technique for difficult airway
management. AFOI requires sedation, anxiolysis, and relief of discomfort without impairing
ventilation, depressing cardiovascular function, a patent airway with blunting reflexes and
spontaneous ventilation, when the airway is difficult. Many agents like fentanyl, midazolam,
ketamine, propofol and remifentanil have been used to facilitate AFOI. This quality
improvement project composed of 13 randomized control trials (RCTs) reviewed different drug
regimens for AFOI anticipated difficult airway, it also included studies examining elective
awake fiberoptic intubation for scheduled surgery. The empirical evidence demonstrated that the
occurrence of desaturation was less with dexmedetomidine or alfentanil when compared against
fentanyl, remifentanil, and propofol. This quality improvement educational module seeks to
assess anesthesia providers knowledge, on the efficacy of drugs, and drug regimens for AFOI.
Anesthesia providers receiving the educational intervention will include Anesthesiologists and
Certified Nurse Anesthetists (CRNA). The sample will include approximately 5-10 participants.
The quality improvement project will involve three phases, pre-assessment testing, an online
educational presentation, and a post-assessment exam. Pre-assessment and post-assessment
testing will be used to measure the effects of the intervention. Statistical analysis will be applied
to assess the knowledge of the educational intervention. It is projected that provider education
will improve, providing the knowledge in dosages, side effects, complications, and
pharmacological therapy needed to optimize sedation when performing an AFOI.
Key terms: awake fiberoptic, awake fiberoptic intubation, awake laryngoscopy, and awake video
laryngoscopy.
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BACKGROUND

Introduction
Tracheal intubation is required for many surgical procedures. Difficult airway
management is a challenge even for the most experienced anesthesia provider. Patients with a
possible or history of difficult airway, such as a positive difficult airway screening, airway
deformities, lesions, tumors, or spinal cord issues will benefit from the use of awake fiberoptic
intubation (AFOI).1-3 The incidence of encountering a difficult airway while attempting to
intubate ranges from 0.3% to 13% which equals, 1 of every 250 patients or 0.4% of cases.1
Difficult intubation and difficult mask ventilation can create a dangerous scenario known as
‘can’t intubate can’t ventilate’ (CICV),2,3 leading to apneic brain injury and death due to
inappropriate management of a difficult airway. Difficult airway management can be an
unforeseen finding as there are several scores and tests which predict its occurrence before the
induction of anesthesia. Several guidelines and techniques have been presented, assessed, and
published to manage AFOI.
AFOI is the gold standard for securing patients’ airway with an expected difficult
airway.4 Performing AFOI requires a level of sedation that limits discomfort, provides anxiolysis
without affecting cardiovascular stability, and impairing spontaneous ventilation.5-18 Conscious
sedation is the desired anesthesia level for an AFOI because it allows for spontaneous ventilation
to be maintained during failed intubation attempts.5 Deep sedation often results in the loss of
spontaneous breathing, leading to hypoxia, cardiovascular compromise, and ultimately death.5-17
One of the significant challenges when seeking to perform AFOI is achieving an optimal
sedation level while maintaining a patent airway that allows the patient to breathe spontaneously.
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AFOI is performed utilizing a flexible fiberoptic scope and it’s success depends on the
experience of the anesthesia provider and the appropriate sedation level of the patient. Multiple
agents such as fentanyl, remifentanil, alfentanil, midazolam, propofol, and ketamine have been
utilized to achieve sedation for AFOI.5-7 These agents can lead to cessation of spontaneous
ventilation, suppress cardiac function, leading to bradycardia, hypotension, hypoxia, and
aspiration.5-7 The sedative or combination of sedatives for AFOI should provide anxiolysis, a
level of amnesia that diminishes the incidence of recall, analgesia, suppress the cough and gag
reflex, with minimal effects on respiratory and cardiovascular stability.5-17
Scope of the problem
Airway complications with the induction of anesthesia are rare but life-threatening when
they occur. CICV occurs in less than 1 in 5,000 general anesthesia cases, 1 out of 50,000 requires
an emergency surgical airway, but this complication accounts for 25% of anesthesia-related
deaths.19 Failed intubations occur 1 in every 2,000 elective settings, 1 in 300 during rapid
sequence intubation (RSI) in obstetrics, 1 in 50 to 100 in the emergency department (ED) and
intensive care unit (ICU). The rate of CICV raises to 1 in 200 in the ED.18 Difficult intubations
are often unexpected and can result in complications leading to patient injury. The median cost
for all admissions coded for difficult intubation was $33,171, compared with a median cost of
$12,940 for all matched admissions without difficult intubation, indicating a cost differential of
$20,231.19
AFOI removes the stimulation caused by direct laryngoscopy due to placement of local
anesthetics with different airway nerve blocks. Still, hypertension and tachycardia are often
reported during the fiberoptic scope’s insertion through the vocal cords. Prolonged intubation
time results in hypercarbia, high blood pressure and increased heart rate. Nevertheless,
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stimulation of the oropharyngeal structures and jaw thrust is considered the main stimulant for
cardiovascular changes.20 Drugs utilized to prepare for AFOI can also cause complications. The
National Audit Project of the Royal College of Anesthetists (NAP4) identified over sedation as a
“significant problem area leading to failed FOI”20 and acknowledged that it “increases the
likelihood of airway obstruction”.20 Hypoxia with a SpO2 < 90% occurs in 14.3% of patients
undergoing AFOI.20
The conventional methods for AFOI, such as the utilization of benzodiazepines and
remifentanil, have their shortcomings.21,22 Airway obstruction caused by over-sedation enhances
endoscopy difficulty, leading to increased risk of airway failure. Equally, over sedation leads to
apnea, creating the same airway risk as when attempting direct laryngoscopy for general
anesthesia.5,20,21 The NAP4 provided multiple reports on remifentanil problems when utilized
with other drugs for sedation.21,22 Remifentanil caused respiratory depression, leading to apnea
and pulmonary arrest.21,22 The NAP4 panel viewed remifentanil as the agent most likely to lead
to these events compared to other sedatives.
Today, multiple agents continue to be utilized to achieve proper sedation during AFOI,
including benzodiazepines, opioids, ketamine, propofol, and dexmedetomidine. The empirical
evidence supports dexmedetomidine for AFOI due to its minimal effect on respiratory depression
and easy titration resulting in a patient that is easily arousable while maintaining spontaneous
ventilation.4,6,7,10,11 Dexmedetomidine is currently utilized for patients in the ICU for sedation
during procedures, including AFOI and regional anesthesia. Dexmedetomidine is a high selective
α2 adrenergic agonist, which possesses analgesic and anxiolytic properties, decreases salivation
with miniscule respiratory depression.5 Dexmedetomidine facilitates its effects on α2-adrenergic
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receptor by activating guanine-nucleotide regulatory binding proteins causing sedation and
anxiolysis within the locus coeruleus which modulates wakefulness.5
Recommendations are varied on maintaining spontaneous ventilation for the CICV
patient during AFOI. This systematic review seeks to find the safest drug or drug combinations
to achieve an adequate level of sedation for AFOI. Certain drugs may need to be avoided
depending on the patient’s history, condition, and American Society of Anesthesiologists (ASA)
classification. The purpose of this systematic review is to review the evidence with a specific
focus on the efficacy, safety profile, drug dosages, and hemodynamic stability for opioids,
benzodiazepines, propofol, ketamine and dexmedetomidine in patients undergoing AFOI.
PICO
(P) In adult patients presenting for awake fiberoptic intubation (I) does an educational
module and algorithm on multimodal pharmacological therapy (C) compared to opioids,
benzodiazepines, propofol and ketamine alone or in combination (C) increase the anesthesia
providers knowledge in dosages, side effects, complications, and pharmacological therapy? The
objective of this systematic review is to develop an educational tool that describes each
pharmacological therapy individually or in combination, providing the drugs most common
dosage, side effects, complications, and adult age range for AFOI.
METHODOLOGY
Information Sources and Search Strategy
A literature search of randomized controlled trials was performed to compare the use of
opioids, benzodiazepines, ketamine, propofol, and dexmedetomidine for AFOI for anticipated
difficult airway in the adult surgical patient. The Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) checklist was used to guide the search and format the
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literature review.23 The literature review seeks to review prior knowledge, identify
inconsistencies, and provide a foundation of knowledge regarding medications and their use in
AFOI.
The search was conducted in three electronic databases including, MedLine (ProQuest),
Excerpt Medica Database (EMBASE), and Cumulative Index of Nursing and Allied Health
Literature (CINAHL). The search terminology included key terms for AFOI such as “awake
fiberoptic”, “awake fiberoptic intubation”, “awake laryngoscopy”, and “awake video
laryngoscopy”. The literature search and screening methodology is summarized in Figure 1 in a
PRISMA illustration. As of October 2020, the search was current. The Medline (ProQuest) data
base yield 176 results, CINHAL stemmed 101 results and EMBASE provided 354 articles.
Duplicates were removed leaving 254 articles to be reviewed. Below, Figure 1 provides a
PRISMA flow diagram that details each phase of the literature review screening process.

10

Figure 1. PRISMA Flow Diagram

Additional records identified
through other sources
(n = 0)

Identification

Records identified through
database searching
(n = 354)

Screening

Records after duplicates removed
(n =100)

Records screened
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Eligibility

Full-text articles assessed
for eligibility
(n = 43)

Studies included in
qualitative synthesis
(n = 13)

Records excluded
(n = 211)

Full-text articles
excluded, with reasons
(n = 27)
10 Wrong Study Design
4 Wrong Outcomes
4 Wrong patient
population
2 Wrong Intervention
measured
2 Systemic Reviews
2 Inappropriate patient
screening
2 Published before
2015
1 Published in Chinese
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Study Selection and Screening
The PICO question was utilized to identify pertinent article titles and abstracts from the
articles selected. The search strategies were limited to randomized control trials (RCTs). A total
of 254 article citations and abstracts were screened and separated into a “Pertinent” folder,
“Supplemental information” folder and “Disregard” folder. Twenty-seven articles were placed
into the “Pertinent” folder, 10 into the “Supplemental” folder, and 211 citations were placed into
the “Disregard” folder. The retrieved citations from the “Supplemental” and “Pertinent” folders
were imported to Mendeley for ease of access and comparison. Duplicate articles were once
again screened and eliminated. Full-text review was performed on the 27 articles that were
identified based on a stringent inclusion and exclusion criteria.
The following inclusion criteria was implemented for potentially relevant studies: (1)
RCTs comparing different methods of sedation for fiberoptic bronchoscopy or tracheal tube
introduction; (2) involving adult patients with predicted difficult airway management; and (3)
published in peer-reviewed journals. The main outcomes considered were hemodynamic changes
that included heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP),
mean arterial pressure (MAP), end tidal carbon dioxide (ETCO2) and oxygen saturation (SPO2),
and achieving a minimal level of two on the Ramsay Sedation Scale (RSS) as this level assures
the patient is cooperative, aware, and relaxed. Other information collected in the management
and preparation of AFOI acquired when available include:
1. Preparation for AFOI such as airway block, inhaled or parental medications used to
precondition airway.
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2. Management of complications such as hypotension, bradycardia, hypoxia, and airway
obstruction.
3. Patient tolerance level.
4. Patient satisfaction after the procedure regarding intubation.
Exclusion criteria included studies done in nonoperating settings, RCTs comparing
different AFOI techniques, and studies involving simulation. Also, articles that utilized
nonstandard medication dosages to achieve an adequate level of sedation for AFOI. Please refer
to Table 1 for further details on inclusion and exclusion criteria.
Table 1: Inclusion and Exclusion Criteria
Inclusion
Population:
• Adults (18-64 years of age)
Type of procedure:
• Awake fiberoptic intubation (AFOI) in patients
screened or with history of difficult airway.
Intervention:
• Studies on the use of IV opioids,
benzodiazepines, opioids, ketamine, propofol,
and Dexmedetomidine to achieve adequate level
of sedation for AFOI
Primary outcomes:
• RSS score of two or greater (Patient is
cooperative, oriented, and tranquil)
• Hemodynamic Stability (No rise greater than
20% (HR, SBP, DBP, MAP, ETCO2 and SPO2).
• Measure of Patients Tolerance level
• Airway Obstruction or Hypoxia
• Number of patients that suffered bradycardia
• Number of patients that suffered hypotension
Type of study:
• English language
• Randomized controlled trials
• Publication date 2015-Present

Exclusion
Population:
• Geriatrics
• Children (<18 years old)
Type of procedure:
• Any other form of intubation
Intervention:
• Medication not utilized IV
for sedation
Outcomes:
• Anything other than
mentioned
Type of study:
• Non-English
• Publication date pre-2015
• Systematic reviews
• Meta-analysis
• Questionnaires
• Dissertations/theses
• Case reports/Studies
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Collection, Analysis, and Data Items
The selected studies were examined in a systematic method. The John Hopkins research
evidence appraisal tool was utilized to evaluate the studies.24 The appraisal tool aids in rating
each article with a quality and evidence level. A quality score of “I” describes an experimental
study, RCT or systematic review of RCTs, with or without meta-analysis.24 Evidence level is
composed of three ratings: “A” or “High” quality stands for reliable, applicable results, study of
adequate sample size with a control and definitive results; “Good” or “B” quality indicates
adequate results, adequate sample size, fairly definitive conclusion based on fairly definitive
literature review; lastly, “C” or “Low” quality signifies poor evidence with unreliable results,
inadequate sample size for study and unclear conclusions.24
The articles underwent a thorough evaluation. An evidence and quality rating were given
based on the John Hopkins’ research evidence appraisal tool as seen in Table 1 below. Only
studies with an evidence level of “I” and a quality level of “A” and “B” were utilized for this
literature review. As mentioned, these levels of studies are RCTs with adequate sample size
providing conclusive and replicable results which provide the highest level of reliability and
validity. Information gathered during evaluation of each RCT was placed in a matrix for
comparison. The matrix included: the study design and method, sample size and setting.
Independent variables included opioids, benzodiazepines, ketamine, propofol, and
dexmedetomidine. Dependent variables included hemodynamics, RSS, cough score and
intubation score, findings, results and conclusion. The headers in the table include the authors,
year published, evidence and quality level based on John Hopkins’ research evidence appraisal
tool and the information extracted from the articles comparing dexmedetomidine as a sole agent
or comparing dexmedetomidine with other drugs or different dosages of a single drug.
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RESULTS
Study Selection
A total of 354 articles were found on the initial search conducted in Medline, EMBASE,
and CINAHL. One hundred articles were eliminated due to duplicates, resulting in 254 articles
left for review. Abstract and title review eliminated 211 articles, a total of 43 articles were
carefully screened and assessed. Utilizing the inclusion and exclusion criteria, 27 articles were
eliminated due to study design, measured outcomes, patient population, intervention, language,
date, and lack of patient screening. The final study selection resulted in 15 articles to address the
PICO question: (P) In adult patients presenting for awake fiberoptic intubation (I) does an
educational module and algorithm on multimodal pharmacological therapy (C) compared to
opioids, benzodiazepines, propofol and ketamine alone or in combination (C) increase the
anesthesia providers knowledge in dosages, side effects, complications and pharmacological
therapy? Table 1 provides a summation of all RCTs utilized to conduct the literature review.
Dexmedetomidine
In 2016, Chopra et al6 evaluated the use of a dexmedetomidine drip versus a control for
patients undergoing AFOI. A double-blinded RCT study on 100 patients between the ages of 1865, ASA I and II underwent AFOI for scheduled elective surgery requiring general anesthesia.6
The study had two groups, the intravenous dexmedetomidine group and a control group. The
intravenous dexmedetomidine group received dexmedetomidine (1 μg/kg) over 10 min followed
by dexmedetomidine infusion at the rate of 0.7 μg/kg/h. Control group, (Group P, n=50) received
IV normal saline bolus (1 ml/kg) over 10 min, followed by normal saline infusion at the rate of
0.7 ml/kg/h. Patient satisfaction score, HR, SBP, DBP, MAP and respiratory parameters were
significantly better in the dexmedetomidine group (P < 0.001). Postintubation wakefulness in the
two groups was comparable (P=0.29).
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A randomized, placebo-controlled, double-blinded, prospective study conducted by
Niyogi et al7 in 2017, included 56 adult patients, ASA I and II, aged 18–50 years, undergoing
elective cervical with cervical spondylotic myelopathy (CSM) undergoing elective cervical
fixation requiring AFOI allocated patients into two groups - Group D and Group C. Group D
patients received dexmedetomidine infusion at a rate of 1 μg/kg for the first 10 min followed by
0.5 μg/kg/h and Group C received 0.9% normal saline infusion in the same manner. The patient’s
alertness, sedation, and cardiorespiratory changes during the procedure were assessed utilizing
the Observer Assessment Awareness and Sedation (OAA/S) scale. On post-operative day one,
the patient’s comfort during AFOI was assessed using a visual analogue scale (VAS). Patients of
Group D had an acceptable level of sedation (OAA/S score: 20 to 17 with greater comfort and
satisfaction (VAS: 40–60), compared to Group C (VAS: 50–90, P < 0.001). Moreover,
hemodynamic parameters were less significantly altered in the dexmedetomidine group during
AFOI. The study concluded that IV dexmedetomidine infusion during AFOI improves patient’s
tolerances with an acceptable level of sedation without significant hemodynamic instability and
respiratory depression.
Dexmedetomidine versus Opioids
Mondal et al10 conducted a double-blind prospective study in 2016, among 60 patients of
either sex, aged 20- 60 years, belonging to ASA I and II, requiring AFOI for elective
laparotomies. Patients were randomly allocated into two groups, Group A received
dexmedetomidine 1 mcg/kg and Group B received Fentanyl 2 mcg/kg over 10 min. Cough score
< 2 was considered as favorable intubation condition, which was achieved in 28 out of 30
patients in Group A, but only in 3 out of 30 patients in Group B. The difference was statistically
significant (P < 0.0001). Better post-intubation score (Score 1) was found in 24 patients of
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Group A and only three patients in Group B. This difference was also statistically significant (P
< 0.0001). A higher RSS was achieved in Group A (3 ± 0.371) than in Group B (2.07 ± 0.254) (P
< 0.0001). The study concluded that dexmedetomidine is more effective than fentanyl in
producing better intubation conditions and sedation along with hemodynamic stability and less
desaturation during AFOI.
In 2017, Hassan & Mahran8 evaluated different doses of dexmedetomidine versus the use
of dexmedetomidine with fentanyl. A RCT included 150 patients, ASA type I and II, ages 18-60
planned for AFOI undergoing general anesthesia for oral cancer surgery. Patients were evenly
allocated into three groups; Group D1: received an infusion of 1 μcg/kg dexmedetomidine
diluted in 50 ml saline over 20 min. Group D2: received an infusion of 2 μcg/kg
dexmedetomidine diluted in 50 ml saline over 20 min. Group DF: received an infusion of 1
μcg/kg dexmedetomidine added to 1 μcg/kg fentanyl diluted in 50 ml saline over 20 min.
Fiberoptic intubation comfort was statistically insignificant between groups (P > 0.05). Group
D2 showed more incidence of airway obstruction than the other two groups. Hemodynamic
parameters such as SBP, DBP, and HR, revealed a significant decrease from baseline until the
time of intubation, after administration of the study drugs, followed by a slight significant
increase after intubation and less than baseline. However, all groups were similar in
hemodynamic values at all-time points with no interaction between them (P > 0.05). The study
concluded that adding a low dose of fentanyl (1μcg/kg) to a low dose of dexmedetomidine can
prevent the risk of airway obstruction associated with increasing the dose of dexmedetomidine
while achieving the same favorable intubation scores.
In 2017, Eldemrdash et al4 conducted a RCT to evaluate and compare dexmedetomidine
or fentanyl efficacy for sedation during AFOI. The study was composed of 60 patients, aged 20 –
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40, ASA I and II separated into two groups, Group D dexmedetomidine 1 mcg/kg, and group F
fentanyl 2 µg/kg; both drugs were diluted with 50 ml saline to be infused over 10 minutes.
Sedation was assessed by (RSS), intubation condition by a cough score and tolerance to
intubation was evaluated by a 1-5 nominal scale. Best RSS was achieved in Group D (3 ± 0.371)
(P < 0.0001). Cough score < 2 achieved in 25 out of 30 patients in Group D (P < 0.0001). Postintubation score (Score 1) was found in 24 patients of Group D (P < 0.0001). Significant increase
in HR (77.767 ± 10.562 beats/min) in Group F (P < 0.0001). Rise in MAP in Group F (92-118)
(P < 0.0001). Twenty-eight patients of Group D were able to maintain SpO2 (>95%) (P <
0.0001). Dexmedetomidine appears to offer better patient tolerance, better preservation of a
patent airway, spontaneous ventilation, and a reduced hemodynamic response to intubation, in
comparison to fentanyl.
In 2020, Baiju et al9 conducted an RCT on 40 patients aged 20–65 years with an ASA
Grade of I, II, and III scheduled for elective surgeries and planned AFOI over 2 years. One group
received fentanyl 2 mcg/kg infusion over 10 min. The other group received dexmedetomidine 1
mcg/kg infusion over 10 min. There was no significant difference in HR, SBP, DBP, MAP, and
oxygen saturation between the two groups at any point of time during the study period (P >
0.05). The time to sedation and the time to intubation were shorter with dexmedetomidine than
with fentanyl. There were no significant differences in cough score, the number of intubation
attempts, HR, SBP, DBP, MAP, and oxygen saturation between the groups.
Liu et al13 conducted an RCT in 2015 comparing remifentanil versus dexmedetomidine.13
The study investigated the efficacy of a modified AFOI method in cases with anticipated difficult
airways. In addition, the efficacy of remifentanil and dexmedetomidine as adjuvants were
compared. Ninety patients ASA II and II were separated between the remifentanil group and
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dexmedetomidine Group. Remifentanil group received a loading dose of remifentanil at 0.75
µg/kg infused at 0.15 µg/kg/min over 5 min, followed by a continuous infusion of 0.1 µg/kg/min.
Patients in the dexmedetomidine group received a loading dose of 1 µg/kg infused over 10 min,
followed by a continuous infusion of 0.3 µg/kg/h. No statistically significant differences were
observed in the sedation scale, intubation times, and patient reactions when comparing the two
groups (P > 0.05). The comfort scores and airway events during intubation did not significantly
differ between the two groups. However, the remifentanil group experienced less coughing, and
less time was required for tracheal intubation when compared with the dexmedetomidine group.
No statistically significant differences were observed in the changes to the MAP, HR at any time
point between the two groups.
In 2020, Jafari et al14 sought to compare alfentanil versus dexmedetomidine in the use of
AFOI. Sixty adult patients between 30 and 55 years old, ASA I and II, with Mallampati score I
and II were randomly allocated into two equal groups (n = 30) to receive either a loading dose of
dexmedetomidine (1 mg/kg) over 10 min, followed by 0.5 mg/kg/h infusion or an alfentanil
loading dose (20 mg/kg) over 60-90 seconds and then repeated 10 mg/kg every 1-2 minutes over
10-20 seconds to reach RSS score greater than three. Primary outcome measures on intubation
scores were assessed by vocal cord movement, limb movement, patient tolerance, cough, and
patient cooperation immediately after intubation. Time taken to achieve sedation, endoscopy
time, intubation time in the alfentanil group was significantly shorter than the dexmedetomidine
group (P < 0.001). Limb movement and cough were more suppressed among the alfentanil group
(P < 0.0001). Alfentanil provided better patient satisfaction than dexmedetomidine (P < 0.007).
The level of patients’ tolerance and cooperation during and immediately after intubation were
higher in the alfentanil group comparing dexmedetomidine (P < 0.0001 and P < 0.005;
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respectively). Nine patients in the dexmedetomidine group and two patients in the alfentanil
group needed to be administered atropine (P < 0.02) to increase the HR, and four patients in the
dexmedetomidine group and no patients in the alfentanil group needed ephedrine to increase
their HR, and blood pressure. MAP in the alfentanil group was significantly more stable than in
patients who received dexmedetomidine (P = 0.0001). Alfentanil provided significantly more
stable intubation scores for AFOI compare with dexmedetomidine and patients were
significantly more satisfied with fewer hemodynamic adverse effects.
Dexmedetomidine versus Fentanyl and Midazolam
Hassani et al11 conducted a RCT in 2018, which included 52 patients between 20-60
years old with ASA I and II, undergoing elective surgery requiring AFOI were randomly
allocated to two groups. Group D (n = 26) received dexmedetomidine 1 mcg/kg in 10 minutes
and then 0.5 mcg/kg/h. Group F (n = 26) received fentanyl 2 mcg/kg and midazolam 1 mg IV.
Hemodynamic variables, SpO2 were evaluated before and after sedation and after intubation.
RSS and patient’s tolerance were evaluated. Lower HR after intubation (P = 0.008) and higher
SpO2 before sedation (P < 0.001) and after intubation (P = 0.02) were observed in
dexmedetomidine group compared to the fentanyl group. The need for propofol for further
sedation was comparable between groups (11.5% vs. 7.7%, respectively; P = 0.63). Both groups
had comparable RSS and tolerance during intubation. Dexmedetomidine compared to fentanyl
and midazolam had comparable sedation with better hemodynamic stability and SpO2 during
AFOI and thus is better than fentanyl-midazolam combination for AFOI.
Yousuf et al12 conducted a RCT in 2017 comparing the effectiveness of dexmedetomidine
versus fentanyl-midazolam combination on sedation and safety during AFOI. A total of 60
patients ASA I and II of either sex, in the age group of 18–60 years having predicted difficult
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intubation undergoing elective surgeries and the patients were allocated to two groups of thirty
patients each. The dexmedetomidine group (Group I, n = 30) received dexmedetomidine 1 μg/kg
over 10 min and the midazolam–fentanyl group (Group II, n = 30) received fentanyl 2 μg/kg plus
midazolam 0.02 mg/kg over 10 min. The demographic characteristics were comparable in the
two groups (P > 0.05). The mean RSS in the dexmedetomidine group was 3.13 ± 0.937 and in
the midazolam fentanyl group was 3.16 ± 0.949, and the comparison between two groups was
statistically insignificant (P = 0.891). Cough scores and postintubation scores were favorable in
dexmedetomidine group than midazolam–fentanyl group and were statistically significant with P
< 0.001 and 0.0001, respectively. Dexmedetomidine also showed better hemodynamics and less
episodes of desaturation when compared to the midazolam-fentanyl group.
Dexmedetomidine in combination with other agents
Kumar et al15 conducted a randomized, double-blind, comparative study in 2019, on 72
cooperative patients aged 15–45 years of either sex, ASA I and II with anticipated difficult
airway (mouth opening <2 cm, thyromental distance <6.5 cm, and Mallampati Class III and IV
for elective surgical procedure. The authors compared two doses of ketamine 20 mg (Group I)
and 40 mg (Group II) with a typical dose of dexmedetomidine at 1 μg/kg body weight, given as
an infusion over 10 min (a solution of 50 ml with normal saline). Group II patients showed less
variation from their baseline values in terms of HR (ranged between 0.73% and 4.75%) and
MAP (ranged between 0% and 3.97%) in comparison to Group I, HR (ranged between 0.09%
and 9.81%) and MAP (ranged between 0.3% and 10.38%). Discomfort during procedure (P <
0.001) and recall of procedure scale (P < 0.001) were found significantly lower in Group II as
compared to Group I. Ketamine 40 mg in comparison to 20 mg with dexmedetomidine provides
better hemodynamic conditions with better tolerance and lower recall to the AFOI.
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Furthermore, Kaur et al16 conducted a blind RCT in 2019, including 100 patients of either
gender aged between 18 to 60 years of age belonging to ASA-I or II, scheduled for elective
surgery under general anesthesia to compare dexmedetomidine with ketamine versus
dexmedetomidine with propofol during AFOI. Two experimental groups consisted of 50 patients
each, both groups received IV dexmedetomidine 1µg/kg over 10 mins. The first group received
dexmedetomidine with ketamine at 0.25 mg/kg IV. Patient in the second group received
dexmedetomidine with propofol at 1mg/kg IV. The study concluded that hemodynamic stability
pertaining to HR, SBP, DBP, MAP while maintaining adequate SpO2 was best maintained in the
dexmedetomidine (1µg/kg) plus ketamine (0.25mg/kg) group. Significant decrease in MAP
during fiberscope and ETT insertion in group dexmedetomidine with propofol (P < 0.001) as
compared to dexmedetomidine with ketamine group. Higher SpO2 levels were maintained in the
dexmedetomidine with ketamine group during fiberscope insertion and endotracheal intubation
(P < 0.05). Patients were more comfortable in group dexmedetomidine with ketamine as
compared to group dexmedetomidine with propofol during fiberscope placement and intubation
(P < 0.05). Increased patient tolerance was observed in the dexmedetomidine with ketamine
group (P < 0.05) and showed better tolerance and comfort while maintaining adequate SpO2
saturation without any hemodynamic alteration.
In 2019, El Morad et al17 conducted a double-blind RCT of 80 patients of either gender,
aged 18- 60 years, ASA I-III, who presented for difficult airway intubation due to laryngeal mass
biopsy under general anesthesia. Two groups were compared, the first group utilized
dexmedetomidine-propofol (group D; n = 40) the second group utilized ketamine-propofol
(group K; n = 40). No statistically significant difference in cough scores were observed between
the two groups (P = 0.611). At baseline measurement (T0), MAP and HR changes in the two
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groups were comparable (P = 0.433 and P = 0.136, respectively). There was a statistically
significant difference between the study groups regarding the changes in hemodynamic
parameters at various points of measurements after infusion of the study medications. Patients in
group D had a statistically significant lower MAP and HR after the loading dose till five minutes
after intubation (from T1 to T6) (P = 0.000). Furthermore, a statistically significant decrease was
observed between baseline values and subsequent MAP and HR measurements in group D (P =
0.000). The study results showed that ketamine-propofol and dexmedetomidine-propofol
combination were suitable and satisfactory for AFOI. However, ketamine-propofol provided
more satisfactory conditions for AFOI than dexmedetomidine; demonstrated by less time to
reach the targeted sedation level (RSS > 3), shorter intubation time with fewer numbers of
intubation trials, and less need of rescue dose of propofol in the ketamine with propofol group as
compared to those of the dexmedetomidine group.
Table 2 Studies Included in Literature Review
Author (Year) &
Level of
Evidence

Study, Participants,
Interventions, &
Setting

Findings in
Dexmedetomidine
Treated Group (D
Group)

Chopra P, Dixit
MB, Dang A,
Gupta V. (2016)
Level 1 Quality B

Double blinded RCT
of 100 healthy patients
between the age
groups 18-65 years.
Patients belonging to
American Society of
Anesthesiologists
Grade I or II, with
Mallampati Grade I or
II, scheduled for
elective surgery
requiring GA. DEX
group, (Group D, n =
50): Received

Mean HR and MAP
decreased in the DEX
group and increased in
the placebo group (P <
0.001). Respiratory rate
decreased in DEX group
and increased in the
placebo group
throughout the AFO (P <
0.001).
RSS was higher in
Group D at every point
of observation until
intubation (P < 0.05).

Findings in the
Other group
(Control, Opioids,
Benzodiazepines,
Propofol/Ketamine)
In Group P,
significantly a
greater number of
patients had
tachycardia P < 0.05
compared with
Group D.
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Niyogi S, Basak
S, Acharjee A,
Chakraborty I.
(2017) Level 1
Quality B

intravenous (IV) DEX
(1 μg/kg) over 10 min
followed by DEX
infusion at the rate of
0.7 μg/kg/h. Placebo
group, (Group P, n =
50) received IV
normal saline bolus (1
ml/kg) over 10 min,
followed by normal
saline infusion at the
rate of 0.7 ml/kg/h.
Randomized, placebocontrolled, doubleblinded, prospective
study was conducted
on 56 adult patients
with cervical
spondylotic
myelopathy (CSM)
undergoing elective
cervical fixation, who
were randomly
allocated into two
groups - Group D and
Group C. Group D
patients received DEX
infusion at a rate of 1
μg/kg for the first 10
min followed by 0.5
μg/kg/h and Group C
received 0.9% normal
saline infusion in the
same manner. Airway
blocks with lignocaine
were given to all
patients before
undergoing AFOI.

Patients in Group D
were significantly more
satisfied than those in
Group P.
*Both groups were
statistically comparable
for hypertension during
the procedure (P = 0.07).

Group D, HR was
significantly decreased
(64.25 ± 8.92/min)
during FOB from
baseline (72 +
12.54/min) (P < 0.001).
DEX group, the changes
in RR were statistically
insignificant (14–
16/min, P = 0.328).
Patients of Group D had
an acceptable level of
sedation (OAA/S score:
20 to 17 with greater
comfort and satisfaction
(VAS: 40–60).
*All the patients of both
groups maintained
arterial SpO within the
satisfactory level (98%–
99%) during the study
period and the changes
were statistically
insignificant (P = 0.321).

N/A
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Hassan ME &
Mahran E. (2017)
Level 1 Quality A

RCT of 150 ASA 1
and 2, ages from 18 to
60 years old and
surgeries dealing with
oral cancer with a plan
for awake nasal
fiberoptic intubation as
an airway management
technique to deal with
the difficult airway
situation in these
patients. This study
was carried out at the
National Cancer
Institute– Cairo
University. Group D1:
Received an infusion
of 1 μcg/kg
dexmedetomidine.
Group D2: Received
an infusion of 2
μcg/kg
dexmedetomidine.
Group DF: Received
an infusion of 1
μcg/kg
dexmedetomidine
added to 1 μcg/kg
fentanyl.

Increasing the dose of
dexmedetomidine
resulted in a significant
increase in airway
obstruction in group D2
(with P = 0.01).
In regards to
hemodynamic
parameters (systolic and
diastolic blood pressure
and HR), all groups were
similar in hemodynamic
values at all-time points
with no interaction
between them (P>0.05).

Group DF resulted
in more patients with
no limb movement
throughout the
procedure (13
patients).

Eldemrdash A,
Gamaledeen N,
Zaher Z, Salem
AA. (2017) Level
1 Quality A

Double blinded
randomized
prospective study was
conducted among 60
patients, aged 20 - 40
years in Aswan
University Hospital,
MP grade III and IV
and TMD < 6.5 cm
were of both sex,
belonging to ASA I
and II, and posted for
elective abdominal

Best RSS was achieved
in Group D (3 ± 0.371)
(P < 0.0001)
Cough score ≤ 2
achieved in 25 out of 30
patients in Group D (P <
0.0001).
Post-intubation score
(Score 1) was found in
24 patients of Group D
(P < 0.0001). 28 patients
of Group D were able to

Significant increase
in HR (77.767 ±
10.562 beats/min) in
Group F (P <
0.0001). Rise in
MAP in group F
(92-118) (P <
0.0001).
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Baiju B, G G, K
P, Antony J,
Jayaprakash R.
(2020) Level 1
Quality B

Mondal S, Ghosh
S, Bhattacharya S,
Choudhury B,
Mallick S, Prasad
A. (2015) Level 1
Quality B

surgeries,
maxillofacial
surgeries. undergoing
AFOI were made into
two groups, group D
Dexmedetomidine 1
mcg/kg, and group F
Fentanyl 2 µg/kg, both
drugs was diluted with
50 ml saline to be
infused over 10
minutes.
Prospective
randomized doubleblind study was done
on 40 patients aged
20–65 years belonging
to ASA Grades 1, 2,
and 3 scheduled for
elective surgeries and
planned for AFOI at a
hospital in central
Kerala. Two groups of
patients with 20
patients in each group
were studied for a
period of 2 years. One
group received
fentanyl 2 mcg/kg
infusion over 10 min.
The other group
received
dexmedetomidine 1
mcg/kg infusion over
10 min.
This randomized
double-blind
prospective study was
conducted on a total of
60 patients scheduled
for elective
laparotomies, ASA I
and II. Two groups:

maintain SpO2 (≥95%)
(P < 0.0001)

There was no significant
difference in HR,
systolic blood pressure,
diastolic blood pressure,
mean arterial blood
pressure and oxygen
saturation between the
two groups at any point
of time during the study
period (P>0.05).
The mean time to
sedation in the fentanyl
group was 7.750 ± 1.499
min and in the
dexmedetomidine group
was 5.250 ± 0.952 min
(P<0.001).

The mean time of
intubation in the
fentanyl group was
14.10 ± 1.861 min
and in the
dexmedetomidine
group was 11.25 ±
1.333 min
(P<0.001).

Cough score ≤2 in 30
patients in Group D, but
only in 3 out of 30
patients in Group F (P <
0.0001).
Better post-intubation
score (Score 1) was

25 patients in Group
F suffered from
significant
desaturation (SpO
≤94%).
Group F rise of
MAP was
statistically
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Group D received
dexmedetomidine 1
mcg/kg and Group F
received fentanyl 2
mcg/kg over 10 min.
Patients in both groups
received
glycopyrrolate 0.2 mg
intravenous,
nebulization with 2%
lidocaine 4 ml over 20
min and 10% lidocaine
spray before
undergoing AFOI.

Hassani V,
Farhadi M,
Mohseni M, et al.
(2018) Level 1
Quality B

In this randomized
clinical trial, 52
patients patients
between 20-60 years
old with ASA I-II
undergoing elective
surgery under general
anesthesia with awake
fiberoptic intubation at
Rasul Akram Hospital,
Tehran, Iran. Group D
(n=26) received
dexmedetomidine 1
mcg/kg in 10 minutes
and then 0.5 mcg/kg/h.
Group F (n=26)
received fentanyl 2
mcg/kg and midazolam
1 mg IV.
Yousuf A, Ahad
This prospective,
B, Mir A, Mir A,
randomized study was
Wani J, Hussain
conducted on a total of
S. (2017)
sixty patients of the
Level 1 Quality A ASA I and II of either
sex, in the age group
of 18–60 years having
predicted difficult

found in 24 patients of
Group D (P < 0.0001).
Higher RSS was
achieved in Group D (3
± 0.371) (P < 0.0001).
26 patients of Group D
were able to maintain
SpO (≥95%) (P <
0.0001).
The post-intubation HR
(75 ± 6.48 beats/min)
decreased significantly
in comparison with
baseline value (77.466 ±
5.75 beats/min) in Group
D (P value 0.005).
Lower heart rate after
intubation (p=0.008) and
higher SpO2 before
sedation (p<0.001) and
after intubation (p=0.02)
were observed in Group
D.

significant (P <
0.0001).
Significant increase
in HR in the postintubation period
(113 ± 16.482
beats/min) in
comparison with the
baseline value
(77.767 ± 10.562
beats/min) in Group
F (P <0.0001).

Group F had
significantly more
cases with no
reaction during
bronchoscopy
(p=0.02).

*Both groups had
comparable RSS and
tolerance during
intubation.

HR of Group D at
postintubation was 87.33
± 9.14 (P < 0.0001).
The mean SBP of Group
D at postintubation was
127.37 ± 7.568.

HR mean for Group
F at postintubation
98.40 ± 4.91 with (P
< 0.0001).
Mean RSS score for
Group F was 3.16 ±
0.949
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Liu HH, Zhou T,
Wei JQ, Ma WH.
(2015)
Level 1 Quality A

intubation undergoing
elective surgeries.
After premedication
and topicalization of
airways,
dexmedetomidine
group (Group D, n =
30) received
dexmedetomidine 1
μg/kg over 10 min and
midazolam–fentanyl
group (Group F, n =
30) received fentanyl 2
μg/kg plus midazolam
0.02 mg/kg over 10
min.

Mean DBP of Group I at
postintubation was 84.00
± 5.705
The mean RSS in Group
D was 3.13 ± 0.937.
27 patients had a
favorable cough score of
≤2.
22 patients in Group D
had a favorable Post
intubation score.
*The comparison
between the two groups
of post intubation HR,
mean SBP, DBP,
desaturation, cough
score, and post
intubation was
significant (P<0.05)
favoring
dexmedetomidine.

The mean SBP of
Group F was 133.2 ±
6.96.
13 patients in Group
F had desaturation
(SpO2 <95%) with P
= 0.024.
4 patients had a
favorable cough
score of ≤2.
5 patients in Group
D had a favorable
Post intubation
score.

RCT. 90 adult patients
with an American
Society of
Anesthesiologists
classification of grade
I‑II underwent a
modified AFOI
procedure following
airway evaluation.
Rem group vs Dex
Group. Rem group
received a loading
dose of 0.75 µg/kg
infused at 0.15
µg/kg/min over 5 min,
followed by a
continuous infu- sion
of 0.1 µg/kg/min.
Patients in the Dex
group received a

The mean time to
achieve sedation with
Dex, was 673.1 sec.

The mean time to
achieve sedation
with Rem was 531.2.

*HR and MAP at five
points no significant
differences between
groups (P>0.05).
*NO statistically
significant differences
were observed in the
sedation scale,
intubation times and
patient reactions when
comparing the two
groups (P>0.05).
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Jafari A,
Kamranmanesh
M,
Aghamohammadi
H, Gharaei B,
Solhpour A
(2020) Level 1
Quality B

Kumar A, Verma
S, Tiwari T,
Dhasmana S,
Singh V, Singh G.
(2019) Level 1
Quality A

loading dose of 1
µg/kg infused over 10
min, followed by a
continuous infusion of
0.3 µg/kg/h.
60 adult patients
between 30 and 55
years old of ASA I &
II, with Mallampati
score I & II who were
undergoing elective
urologic surgery.
allocated into two
equal groups (n = 30)
to receive either a
loading dose of
dexmedetomidine (1
mg/kg) over 10 min,
followed by 0.5
mg/kg/h infusion or
alfentanil a loading
dose (20 mg/kg) over
60-90s and then
repeated 10 mg/kg
every 1-2 min over 1020s to reach Ramsay
Sedation Scale (RSS)
≥3.
RCT-Randomized,
double-blind,
comparative study was
conducted in 72
cooperative patients
aged 15–45 years of
either sex ASA I and
II with anticipated
difficult airway
(mouth opening <2
cm, thyromental
distance <6.5 cm, and
Mallampati Class III
and IV) posted for
elective surgical

7 patients had no cough
in dexmedetomidine
group comparing 21
patients in alfentanil
group (p < 0.0001).

Time taken to
achieve sedation,
endoscopy time,
intubation time in
the alfentanil group
(p<0.001).
HR and MAP decreased Limb movement and
significantly the end of
cough more
drug infusion (RSS ≥3), suppressed among
dexmedetomidine group the alfentanil group
(p = 0.001).
(p < 0.0001).
Alfentanil provided
better patient
satisfaction (p <
0.007).
{atients’ tolerance
and cooperation
during and
immediately after
intubation were
higher in the
alfentanil group (p <
0.0001).
There was a significant
Patients of Group II
difference in mean HR
were deeply sedated
in comparison to
and showed better
baseline values in Group tolerance to
I at all points (P < 0.001) intubation (P <
except at 2 min (P =
0.001).
0.147).
Cough was less
Group I HR variations
severe in terms of
(ranged between 0.09%
grading described
and 9.81%).
before in Group II (P
MAP in Group I showed = 0.023).
a declining trend in
Significantly higher
comparison to the
proportion of
baseline values at all
patients of Group II
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procedure. Two
Groups: Group I
(dexmedetomidine 1
μg/kg + ketamine 20
mg) or Group II
(dexmedetomidine 1
μg/kg + ketamine 40
mg) of 36 patients
using computergenerated random
table.

Kaur B, Garg A,
Kumar P, Yadav
DN (2019) Level
1 Quality B

times of observation (P
< 0.001).

was easiest to
intubate (P = 0.041).
Group II patients
Level of discomfort was showed less
more and statistically
variation from their
significant (P < 0.001) in baseline values in
Group I.
terms of HR (ranged
between 0.73% and
4.75%)
MAP in Group II
showed an uprising
trend in comparison
to baseline values at
all times (P < 0.001,
at 10 min after
intubation P =
0.033)
Group II patients
showed less
variation from their
baseline values in
terms of MAP
(ranged between 0%
and 3.97%)
There was lesser
recall of fiberscopy
procedure in Group
II (P < 0.001),
Blind RCT of 100 total There is better
Significant decrease
patients (ASA I and
hemodynamic stability
in MAP during
ASA II), study was
pertaining to HR, SBP,
fiberscope insertion
conducted in
DBP, MAP while
and ETT insertion in
Department of
maintaining oxygen
group DP (P value=
Anesthesia and
saturation in
<0.001) as compare
intensive care,
dexmedetomidine
to group DK.
Government Medical
(1µg/kg) plus ketamine
College, Rajindra
(0.25mg/kg) group.
Hospital, Patiala: Two Higher SpO2 levels
experimental groups
where maintained in the
50 patient in each
DK group during
experimental group.
fiberscope insertion and
Both received IV
endotracheal intubation
dexmedetomidine
(p<0.05).
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1µg/kg over 10 mins.
Group-DK patients
received ketamine
0.25 mg/kg IV and
Group-DP patients
received propofol
1mg/kg IV.
El Mourad MB,
Elghamry MR,
Mansour RF,
Afandy ME.
Comparison of
intravenous
dexmedetomidinepropofol versus
ketofol for
sedation during
awake fiberoptic
intubation: A
prospective,
randomized study.
2019

Double-blind RCT of
80 patients of either
gender, aged 18 - 60
years, ASA I-III, and
difficult airway
intubation due to
laryngeal mass who
were candidates for
laryngeal mass biopsy
under general
anesthesia. Two
groups the
dexmedetomidinepropofol (group D; n =
40) or ketofol (group
K; n = 40).

Patients were more
comfortable in group
DK as compare to group
DP during fiberscope
and intubation (p<0.05).
Better patient tolerance
was observed in group
DK (p<0.05).
Patients in group D had
statistically significant
lower MAP and HR after
the loading dose till five
minutes after intubation
(from T1 to T6) (P =
0.000).

*No statistically
significant difference in
cough scores were
observed between the
two groups (P = 0.611).
No hypoxic episodes
(SpO2 < 92%) or apneic
attacks were noted.
Patients’ satisfaction
levels were similar in the
two groups (P = 0.687).

Time to reach RSS ≥
3 and intubation
time were
significantly shorter
(P = 0.000*) with
fewer number of
intubation attempts
in the K group.
The number of
patients that needed
rescue doses of
propofol was also
significantly less in
group K (P = 0.035).

DISCUSSION OF LITERATURE REVIVIEW
Summary of the Evidence
This quality improvement project included the review of 13 RCTs assessing different
drug regimens utilized during AFOI for anticipated difficult airway in patients scheduled for
surgery. Dexmedetomidine was the most studied drug for AFOI. Dexmedetomidine was
compared to normal saline, various opioids and IV anesthetics administered in different dosages,
combinations, and associations, throughout the multiple RCTs. Chopra et al6 and Niyogi et al7
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each conducted a double-blinded RCT in adults 18 and older, ASA I and II, utilizing a
dexmedetomidine IV bolus followed by a dexmedetomidine drip and compared it against the use
of normal saline. Dexmedetomidine provided optimum conditions and conscious sedation during
AFOI. Both studies concluded that IV dexmedetomidine infusion during AFOI improves
patient’s tolerances with an acceptable level of sedation without significant hemodynamic
instability and respiratory depression while maintaining stable hemodynamics.
Dexmedetomidine was compared versus fentanyl in three studies, Mondal et al10 and
Eldemrdash et al4 both agree that dexmedetomidine provides the best patient tolerance, maintains
a patent airway and spontaneous respiration with reduce hemodynamic effects when compared to
fentanyl. Unfortunately, Baiju et al9 concluded that were no significant differences in the use of
fentanyl versus dexmedetomidine for AFOI. Hassani et al11 and Yousuf et al12 both conducted a
RCT comparing dexmedetomidine versus the use of fentanyl and midazolam. Dexmedetomidine
provided better hemodynamic stability, less episodes of desaturation, cough scores and post
intubation scores when compared to the fentanyl-midazolam group. Hassan and Mahran8
evaluated different IV doses of dexmedetomidine versus the use of IV dexmedetomidine along
with IV fentanyl drip and concluded that the use of a dexmedetomidine infusion of 1 μcg/kg with
a 1 μcg/kg fentanyl diluted in 50 ml saline over 20 minutes is safer than raising the dose of
dexmedetomidine to 2 μcg/kg as it prevents the risk of airway obstruction seen with the higher
dose of dexmedetomidine. Remifentanil provided less coughing and faster intubation times when
compared to dexmedetomidine in the study conducted by Lie et al13. There were no statistically
significant differences in hemodynamics, patient reactions, or patient tolerance between the two
groups. In the study conducted by Jafari et al14, alfentanil proved to be superior when compared
to dexmedetomidine. Alfentanil provided shorter intubation time, suppressed limb movement
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and cough. Patient satisfaction, tolerance and cooperation were better with alfentanil than
dexmedetomidine.
In the RCT completed by Kaur et al16, the researchers compared dexmedetomidine with
ketamine versus the use of dexmedetomidine with propofol. Dexmedetomidine with ketamine
was superior as patients showed increased comfort, tolerance, and hemodynamic stability while
maintaining adequate SpO2. Morad et al17 studied the difference between ketamine-propofol and
dexmedetomidine-propofol; both combinations were suitable and satisfactory for AFOI.
However, the ketamine-propofol group provided more satisfactory conditions for AFOI than
dexmedetomidine as it reached the target sedation level faster and shorter intubation time. Kumar
et al15 identified that when utilizing dexmedetomidine with ketamine, the best dose of IV
ketamine for AFOI is 40 mg instead of 20 mg. The group given 40 mg of ketamine showed
better hemodynamic stability, lower discomfort and recall during the procedure.
Limitations
This quality improvement project has some limitations. The main limitation
is the inability to perform a formal synthesis to identify the best approach for every step of AFOI
due to the array of the available studies. A meta-analysis was performed only for few, more
homogeneous results, and its findings should be interpreted with caution. Furthermore, given that
the success rate of AFOI was high throughout the different methods and the complications were
rare in all the RCTs, no specific strategy could be declared superior to the others, and more
extensive studies are required. The use of dexmedetomidine when compared to opioids, ketamine
and propofol improved AFOI intubation outcomes, but this does not mean the other methods are
unsafe or failed to provide the appropriate conditions to execute AFOI successfully.
Additionally, major life-threatening adverse events were collected in the different RCTs without
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standardized definitions. A second limit is the reasonably low number of patients included in all
the randomized controlled trials. This quality improvement project has relevant strengths; as it
sought to identify the safety and effectiveness in the best pharmacological approach to AFOI. All
evidence was based only on RCTs, many of them comparing dexmedetomidine to other current
practices for AFOI.
Recommendations
This quality improvement project focused on AFOI, but recently the use of video
laryngoscope for awake intubation has been found feasible and safe. New equipment and
intubation techniques should be studied as fiberoptic intubation may soon become obsolete due
to technological advances. The success of dexmedetomidine for AFOI is prominent throughout
this project. Hurtado et al25 has developed a protocol for the use of dexmedetomidine, see below
Figure 2. Dexmedetomidine possesses unique properties which render it suitable for sedation and
analgesia during the perioperative period. It can be utilized as a premedication, an anesthetic
adjunct for general and regional anesthesia, or postoperative sedative in which analgesia is
similar to benzodiazepines. Dexmedetomidine is a highly selective potent α2-adrenoceptor
agonist providing sedative, analgesic, and anxiolytic properties and reduced salivary secretion,
with minimal respiratory depression.25 No clinically relevant respiratory depression has been
reported. Dexmedetomidine provides hemodynamic and sympathoadrenal stability by reducing
the circulating catecholamines, attenuating the response to endotracheal intubation without
completely abolishing the cardiovascular response.25 As seen through the literature, a sedation
regimen using low dose dexmedetomidine combined with titrated doses of benzodiazepines,
opioids, ketamine, and propofol has successfully been used for airway manipulation. A target-
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controlled infusion can provide consistent pharmacodynamics effects with safe and predictable
sedation levels.25
Figure 2 Awake Fiberoptic Intubation - Adult Treatment Protocol by Hurtado et al25.
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CONCLUSION
A protocol for AFOI is difficult to identify as there are many drugs and dosages utilized.
A wide range of approaches can be effective and safe. Translating an evidence based protocol for
the clinician will depend on the providers knowledge and choice of pharmacological therapy.
Also, the choice of drugs utilized will be dependent on the patient’s co-morbidities and ASA
classification. This quality improvement project sought to identify what drug regimen provided
the best conditions for AFOI. Throughout the literature, dexmedetomidine was the most studied
drug compared to each study versus another pharmacological regimen. It is concluded that
dexmedetomidine is effective, well-tolerated, associated with better intubation conditions, and
reduced recall for AFOI; because of this, it is a vital drug to consider when preparing to conduct
an AFOI.
IMPLEMENTATION
The primary objective of this quality improvement project is to assess the healthcare
providers' current knowledge in AFOI drug regimen and provide empirical evidence on drugs
currently being utilized successfully to perform AFOI. To successfully achieve the goal of this
quality improvement project, a series of actions will be conducted that involved a specific group
of anesthesia providers willing to participate in the intervention. These actions will be identified
in the sections below in determining the study outcome.
Settings and Participants
The study took place at Mount Sinai Medical Center located in Miami Beach, Florida and
will solely focus on Miami Beach Anesthesiology Associates (MBAA). MBAA is a privately
owned anesthesia practice that provides anesthesia services at Mount Sinai Medical Center, the
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primary study participants will be Anesthesiologists and CRNAs. The participants will be
contacted and recruited through the MBAA email list making participation completely voluntary.
The recruited participants will be provided a survey link with the educational intervention which
consists of a pre-test, voice over PowerPoint educational module and post-test. All participants
will be asked to provide feedback regarding their experiences with the educational program. The
anticipated sample size will be between 5-10 participants.
Description of Approach and Project Procedures
The primary methodology of the project is to administer an online educational
intervention composed of a narrated PowerPoint to providers that focus on the benefits of
varying medications and their use during AFOI. A survey composed of three phases will be
distributed via email to the email list provided by MBAA. The first phase of the project will be
composed of a preassessment test that will collect demographic data and identify the current
drugs and drug regimen utilized by the providers when conducting an AFOI. Existing knowledge
of this process will be identified using the preassessment survey, the data collected will be
utilized to compare the impact achieved by the voice over PowerPoint presentation.
Once the surveyor completes the pre-assessment in phase one, the second phase will
contain a narrated PowerPoint presentation. The primary means of learning will be an online
PowerPoint presentation with information on the empirical evidence regarding different drugs
and drugs regimens currently utilized for AFOI. The surveyor will be able to click and view the
presentation. Current literature will focus on the utilization of dexmedetomidine, alfentanil,
propofol, ketamine and midazolam for AFOI. The presentation will focus on the drug regimen
that provided the most optional conditions for AFOI which were dexmedetomidine and alfentanil
as well as provide data comparing the other drugs and their effects when utilized for AFOI.
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The third phase of the project will involve the completion of the post-assessment test to
identify the learned knowledge of the project and how the providers felt about the information
presented in the PowerPoint presentation. The data collected will provide feedback regarding the
impact of the educational intervention and will determine the efficacy of the participants
learning. The pre- and post-assessment will be compared and analyzed in extracting relevant
information regarding the effectiveness of the online intervention. At the end of the educational
tool, feedback will also demonstrate if the educational module requires changes going forward
and if the providers will benefit from future projects being presented in an online format in the
future.
Protection of Human Subjects
For this quality improvement project, the recruitment population will include
Anesthesiologists and CRNAs that are part of the MBAA who work with patients at Mount Sinai
Medical Center. The study population is essential because anesthesia providers perform AFOI
when is warranted for surgical cases. Recruitment activities will be conducted by email
invitations to all anesthesiologists and CRNAs currently employed and practicing at Mount Sinai
Medical Center. MBAA will provide their email list allowing their anesthesia members to be
utilized for this educational intervention. If the anesthesia providers agree to participate, they
will click on the link provided in the email which will prompt the providers to complete the
three-phase survey. There will be no penalties if any participants who decide to withdraw from
the QI project. There are no perceived risks to the study as it only requires the time spent by each
participant in the educational intervention.
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Data Collection
For the quality improvement project, the primary instruments to be used will include a
pre-assessment and post assessment assessing knowledge to determine the effects of the
intervention. Both tests will be conducted by utilizing a three-phase survey developed in
Qualtrics. The survey will be composed of the pre-assessment, followed by the video
presentation and post-assessment. The data collected will determine if participants have a clear
understanding of the most effective drugs and drug regimen for AFOI based on the most recent
data. The pre-assessment survey and post assessment survey will be the same composed of 15
questions that focuses on current practice and baseline knowledge using Qualtrics. In this
manner, the pretest survey will gauge knowledge and attitudes in the educational program while
the post-test survey will determine if the participants have learned from the intervention and
application of their knowledge to the surgical practice environment. The instrument reliability
and validity will be measured in accordance with the intervention and its effectiveness for the
providers. The data collected will be confidential and no subject identifiers will be recorded
during any component of the study.
Data Management and Analysis Plan
The co- investigator for the project will be the DNP student who will be responsible for
administering the survey. The investigator conducted the statistic that will be utilized to evaluate,
compare, and analyze the pre-assessment and post assessment. Each question will be compared
and analyzed, and the responses recorded to identify the knowledge base before and after the
intervention was provided. Absolutely no personal identifiers will be recorded or requested, this
assures the protection of the study participants confidentiality. The impact of the intervention
will be measured solely on the results of the pre- and posttest survey questions. Through
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statistical analysis, the study results will likely identify patterns that will be used to determine the
effectiveness of educational intervention and how it affects all clinicians’ actions and behaviors.
The co-investigator will store the data collected in a password-protected laptop computer.
IMPLEMETATION RESULTS
Pre/Post-Test Demographics
The pre/post-test demographics are show in Table 3, shown below.
Table 3: Pre/Post-Test Participant Demographics
Demographics
Total Participants
Gender
Male
Female
Age
25-35
36-45
46-55
56-66
Ethnicity
Latino/a
Caucasian
African American
Asian
Position/Title
CRNA
MD/DO
Years of Experience
Less than 1 year
1 to 5 years
6 to 10 years
More than 10 years

n (%)
8 (100%)
6 (100%)
2 (25%)
3 (37.5%)
4 (50%)
0 (0%)
1 (12.5%)
6 (75%)
0 (0%)
1 (12.5%)
1 (12.5%)
7 (87.5%)
1 (12.5%)
0
4 (50%)
2 (25%)
2 (25%)

There were eight participants in the pretest and posttest demographics, all the participants
completed the survey and reviewed the online narrated PowerPoint presentation. The age ranges
represented were 25 through 35 years old’s (n=3, 37.5%), 36 through 45 years was the most
represented age group (n=4, 50%) and 56 through 66 (n=1, 12.5%). Most of the participants were
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male (n=6, 75%), as opposed to female (n=2, 25%). There were also a range of ethnicities
represented: African American (n=1, 29.63%), Asian (n=1, 12.5%), and Latino/a (n=1, 12.5 %).
Information was obtained regarding the participant’s role at the clinic. Most of the participants
were CRNAs (n=7, 87.5%) and one MD (n=1, 12.5%). The participants were questioned about
the length of time practicing, finding that the practice period ranged: less than one year (n=0,
0%), 1 to 5 years (n=4, 50%), 6 to 10 years (n=2, 25%), and more than 10 years (n=2, 25%).
Pre-Test Identification of current knowledge of medications utilized for AFOI
This section of the survey focuses on identification of the current drugs being utilized
when performing an AFOI and the current knowledge on dexmedetomidine and alfentanil. The
most utilized drug classes are benzodiazepines (n=7, 87.5%), and dexmedetomidine (n=7,
87.5%), followed by ketamine (n=5, 62.5%) and lastly opioids (n=1, 12.5%). The most utilized
opioids if one is administered are remifentanil (n=7, 87.5%) and fentanyl (n=1, 12.5%). The
mechanism of action of dexmedetomidine is well known by these participants, the question was
answered correctly by all eight participants (n=8, 100%). When asked about the location of the
brain where dexmedetomidine functions and dexmedetomidine side effects more than half of the
study participants answered correctly (n=5, 62.5%). Only half of the study participants (n=4,
50%) knew the mechanism of action of alfentanil which based on recent studies should be the
opioid utilized when performing AFOI.
Table 4: Difference in Pre- and Post-Test Knowledge
Questions
Dexmedetomidine Mechanism of Action?
Where does dexmedetomidine work in the brain?
The most common side effects of dexmedetomidine
Which sedative provides optimum sedation for awake fiberoptic
while maintain spontaneous ventilation?

Pretest
100%
62.5%

Posttest
100%
100%

Difference
0
48.5%

62.5%

100%

48.5%
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Which drug according to recent RCTs provides optimum
conditions for awake fiberoptic intubation?
Alfentanil’s mechanism of action
What is the best initial loading dosage of alfentanil for awake
fiberoptic

50%

87.5%

37.5%

50% 62.5%
37.5% 62.5%

12.5%
25%

In Table 4, knowledge is compared between the pre-test and post-test based on the
percentage of participants that answered the questions correctly. Overall, the knowledge of the
participants did improve after watching the narrated PowerPoint presentation as this is reflected
by higher scores in all questions for the post test. The mechanism of alfentanil had the lowest
percentage increase (n=1, 12.5%) with only one more person answering correctly on the post
test. However, there was a (25%) increase in participants that were able to identify the best
recommended dosage of alfentanil for AFOI in the post test. Lastly, the questions tailored
towards the knowledge of dexmedetomidine all achieved a (100%) on the post test.
Table 5: Utilization of Dexmedetomidine and Alfentanil for AFOI

How likely are you to utilize dexmedetomidine
and alfentanil for awake fiber optic intubation?

Pre-test

Post-test

Difference

62.5%

87.5%

25%

It was noted that practitioners are more likely to utilize dexmedetomidine and alfentanil
based on the post-test results. This result suggests that the narrated PowerPoint presentation
provided the necessary information leading to practitioners feeling incline to incorporating these
two medications into their AFOI drug regimen.
Summary
Overall, the results reflected an improvement in knowledge based on the pre-test and
post-test scores. Knowledge showed an average improvement of (24.5%). The post-test
demonstrated that (25%) of participants are “Extremely Likely” to incorporate dexmedetomidine
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and alfentanil to their drug regimen when performing AFOI. The information provided allowed
the participants to feel comfortable in utilizing dexmedetomidine and alfentanil for their AFOI.
Based on the results the intervention increased the anesthesia providers knowledge in drug
dosages, side effects, complications, and pharmacological therapy.

Summary
100
90
80
70
60
50
40
30
20
10
0
Knowledge

Utilization of dexmedetomidine and alfentanil
Pre-test

Post-test

IMPLEMENTATION DISCUSSION
Limitations
Limitations of the study include a small sample size; the survey was emailed to the
MBAA email list which was composed of 31 emails but only 8 participants completed the study.
A larger sample size is preferable to strengthen the results of the study as well as provide a
sample population that reflects the anesthesia providers at Mount Sinai Medical Center. The
survey link which contained the pre-test, narrated PowerPoint presentation and post-test was
online available for two weeks, increasing the timeline may have generated more responses. The
email with the request to participate in the study was sent only once, follow up emails might
have also aided in generating more responses. Lastly, the project was implemented completely
online hindering its delivery by other methods.
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Future Implications to Advanced Nursing Practice
The outcomes of the study supported an increase in knowledge in determining strategies
available to anesthesia providers for disseminating information on new drug regimen, dosages,
side effects, complications, and pharmacological therapy for AFOI. Improving knowledge of
drugs and drug regimen utilized for AFOI impacts anesthesia providers to utilize the empirical
evidence for best practice and patient safety. Published articles encompass different topic areas
and its imperative to provide a method that effectively translates the research to practice for
anesthesia providers.

44

References
1. Apfelbaum JL, Hagberg CA, Caplan RA, et al. Practice guidelines for management of the
difficult airway: an updated report by the American Society of Anesthesiologists Task
Force on Management of the Difficult Airway. Anesthesiology. 2013;118(2):251-270.
doi:10.1097/ALN.0b013e31827773b2
2. Kheterpal S, Martin L, Shanks AM, Tremper KK. Prediction and outcomes of impossible
mask ventilation: a review of 50,000 anesthetics. Anesthesiology. 2009;110:891–897.
3. Kheterpal S, Healy D, Aziz MF, et al. incidence, predictors, and outcome of difficult
mask ventilation combined with difficult laryngoscopy: a report from the multicenter
perioperative outcomes group. Anesthesiology. 2013;119(6):1360-1369.
doi:10.1097/ALN.0000435832.39353.20
4. Eldemrdash A, Gamaledeen N, Zaher Z, Salem AA. A Comparative Study between
Dexmedetomidine versus Fentanyl on Intubating Conditions and Side Effects during
Awake Fiberoptic Nasal Intubation under Topical Anesthesia in Patients Underwent
Elective Surgical Operation. Open J Anesthesiol. 2017;07(12):415-425.
doi:10.4236/ojanes.2017.712043
5. Hurtado E. Proposal for a Protocol for Awake Fiberoptic Intubation in Adult with
Dexmedetomidine. SOJ Anesthesiol Pain Manag. 2017;4(2):1-7. doi:10.15226/2374684x/4/2/00145
6. Chopra P, Dixit MB, Dang A, Gupta V. Dexmedetomidine provides optimum conditions
during awake fiberoptic intubation in simulated cervical spine injury patients. J
Anaesthesiol Clin Pharmacol. 2016;32(1):54-58. doi:10.4103/0970-9185.175666

45

7. Niyogi S, Basak S, Acharjee A, Chakraborty I. Efficacy of intravenous dexmedetomidine
on patient’s satisfaction, comfort and sedation during awake fibreoptic intubation in
patients with cervical spondylotic myelopathy posted for elective cervical fixation. Indian
J Anaesth. 2017;61(2):137-143. doi:10.4103/0019-5049.199856
8. Hassan ME, Mahran E. Evaluation of different doses of dexmedetomidine alone versus
the combination of dexmedetomidine and fentanyl in sedation during awake fiberoptic
intubation in oral cancer surgery patients: A prospective, randomized, double-blind
clinical trial. Saudi J Anaesth. 2017;11(2):196-202. doi:10.4103/1658-354X.203013
9. Baiju B, G G, K P, Antony J, Jayaprakash R. A prospective randomized controlled study
to assess the efficacy of fentanyl and dexmedetomidine for conscious sedation in awake
fiberoptic intubation. Natl J Physiol Pharm Pharmacol. 2020;10(0):1.
doi:10.5455/njppp.2020.10.07201202028072020
10. Mondal S, Ghosh S, Bhattacharya S, Choudhury B, Mallick S, Prasad A. Comparison
between dexmedetomidine and fentanyl on intubation conditions during awake fiberoptic
bronchoscopy : A randomized double-blind prospective study. 2015;31(2):212-216.
doi:10.4103/0970-9185.155151
11. Hassani V, Farhadi M, Mohseni M, et al. Comparing the Efficacy of Dexmedetomidine
versus Fentanyl and Midazolam During Awake Fiberoptic Intubation. Arch Anesthesiol
Crit Care. 2018;4(4 SE-Research Article(s)).
https://aacc.tums.ac.ir/index.php/aacc/article/view/195.
12. Yousuf A, Ahad B, Mir A, Mir A, Wani J, Hussain S. Evaluation of effectiveness of
dexmedetomidine and fentanyl-midazolam combination on sedation and safety during

46

awake fiberoptic intubation: A randomized comparative study. Anesth Essays Res.
2017;11(4):998. doi:10.4103/aer.aer_150_17
13. Liu HH, Zhou T, Wei JQ, Ma WH. Comparison between remifentanil and
dexmedetomidine for sedation during modified awake fiberoptic intubation. Exp Ther
Med. 2015;9(4):1259-1264. doi:10.3892/etm.2015.2288
14. Jafari A, Kamranmanesh M, Aghamohammadi H, Gharaei B, Solhpour A. Alfentanil or
dexmedetomidine , which one works better for awake fi beroptic intubation ? Trends
Anaesth Crit Care. 2020;33:6-11. doi:10.1016/j.tacc.2020.05.006
15. Kumar A, Verma S, Tiwari T, Dhasmana S, Singh V, Singh G. A comparison of two
doses of ketamine with dexmedetomidine for fiberoptic nasotracheal intubation. Natl J
Maxillofac Surg. 2019;10(2):212. doi:10.4103/njms.NJMS_86_18
16. Kaur B, Garg A, Kumar P, Yadav DN. Comparison of Dexmedetomidine Plus Ketamine
Combination with Dexmedetomidine Plus Propofol for Awake Fiberoptic Nasotracheal
Intubation: A Prospective Randomised and Controlled Clinical Trial. Int J Innov Res Med
Sci. 2019;4(01):71-75. doi:10.23958/ijirms/vol04-i01/539
17. El Mourad MB, Elghamry MR, Mansour RF, Afandy ME. Comparison of intravenous
dexmedetomidine-propofol versus ketofol for sedation during awake fiberoptic
intubation: A prospective, randomized study. Anesthesiol Pain Med. 2019;9(1):1-8.
doi:10.5812/aapm.86442
18. Cook TM, Macdougall-Davis SR. Complications and failure of airway management. Br J
Anaesth. 2012;109(SUPPL1):68-85. doi:10.1093/bja/aes393

47

19. Phillips K, Moucharite M, Wong T, May R. Cost burden associated with difficult
intubation in the United States. Trends Anaesthesia Critical Care. 2020;30:e131.
doi:10.1016/j.tacc.2019.12.320
20. Wong J, Lee JSE, Wong TGL, Iqbal R, Wong P. Fibreoptic intubation in airway
management: a review article. Singapore Med J. 2019;60(3):110-118.
doi:10.11622/smedj.2018081
21. Royal College of Anaesthetists. 4th National Audit Project of the Royal College of
Anaesthetists. Major complications of airway management in the UK. Report and
findings. 2011. Mar, [Accessed July 20, 2016]. Available at:
http://www.rcoa.ac.uk/system/files/CSQ-NAP4-Full.pdf .
22. Cook TM, Woodall N, Frerk C; Fourth National Audit Project. Major complications of
airway management in the UK: results of the Fourth National Audit Project of the Royal
College of Anaesthetists and the Difficult Airway Society. Part 1: anaesthesia. Br J
Anaesth. 2011;106(5):617-631. doi:10.1093/bja/aer058
23. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic
reviews and meta-analyses of studies that evaluate healthcare interventions: explanation
and elaboration. BMJ. 2009;339:b2700. doi:10.1136/bmj.b2700
24. Dang D, Dearholt SL. Johns Hopkins Nursing Evidence-Based Practice, Third Edition:
Model and Guidelines. 3rd ed. Sigma Theta Tau International; 2017.
25. Hurtado E. Proposal for a Protocol for Awake Fiberoptic Intubation in Adult with
Dexmedetomidine. SOJ Anesthesiol Pain Manag. 2017;4(2):1-7. doi:10.15226/2374684X/4/2/00145

48

Appendix A: PRISMA Flow Diagram

Additional records identified
through other sources
(n = 0)

Identification

Records identified through
database searching
(n = 354)

Screening

Records after duplicates removed
(n =100)

Records screened
(n = 254)

Included

Eligibility

Full-text articles assessed
for eligibility
(n = 43)

Studies included in
qualitative synthesis
(n = 13)

Records excluded
(n = 211)

Full-text articles
excluded, with reasons
(n = 27)
10 Wrong Study Design
4 Wrong Outcomes
4 Wrong patient
population
2 Wrong Intervention
measured
2 Systemic Reviews
2 Inappropriate patient
screening
2 Published before
2015
1 Published in Chinese
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Appendix B Matrix Table
Table 2 Studies Included in Literature Review
Author (Year) &
Level of
Evidence

Study, Participants,
Interventions, &
Setting

Findings in
Dexmedetomidine
Treated Group (D
Group)

Chopra P, Dixit
MB, Dang A,
Gupta V. (2016)
Level 1 Quality B

Double blinded RCT
of 100 healthy patients
between the age
groups 18-65 years.
Patients belonging to
American Society of
Anesthesiologists
Grade I or II, with
Mallampati Grade I or
II, scheduled for
elective surgery
requiring GA. DEX
group, (Group D, n =
50): Received
intravenous (IV) DEX
(1 μg/kg) over 10 min
followed by DEX
infusion at the rate of
0.7 μg/kg/h. Placebo
group, (Group P, n =
50) received IV
normal saline bolus (1
ml/kg) over 10 min,
followed by normal
saline infusion at the
rate of 0.7 ml/kg/h.
Randomized, placebocontrolled, doubleblinded, prospective
study was conducted
on 56 adult patients
with cervical
spondylotic
myelopathy (CSM)
undergoing elective

Mean HR and MAP
decreased in the DEX
group and increased in
the placebo group (P <
0.001). Respiratory rate
decreased in DEX group
and increased in the
placebo group
throughout the AFO (P <
0.001).
RSS was higher in
Group D at every point
of observation until
intubation (P < 0.05).
Patients in Group D
were significantly more
satisfied than those in
Group P.

Niyogi S, Basak
S, Acharjee A,
Chakraborty I.
(2017) Level 1
Quality B

Findings in the
Other group
(Control, Opioids,
Benzodiazepines,
Propofol/Ketamine)
In Group P,
significantly a
greater number of
patients had
tachycardia P < 0.05
compared with
Group D.

*Both groups were
statistically comparable
for hypertension during
the procedure (P = 0.07).

Group D, HR was
significantly decreased
(64.25 ± 8.92/min)
during FOB from
baseline (72 +
12.54/min) (P < 0.001).
DEX group, the changes
in RR were statistically

N/A
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Hassan ME &
Mahran E. (2017)
Level 1 Quality A

cervical fixation, who
were randomly
allocated into two
groups - Group D and
Group C. Group D
patients received DEX
infusion at a rate of 1
μg/kg for the first 10
min followed by 0.5
μg/kg/h and Group C
received 0.9% normal
saline infusion in the
same manner. Airway
blocks with lignocaine
were given to all
patients before
undergoing AFOI.
RCT of 150 ASA 1
and 2, ages from 18 to
60 years old and
surgeries dealing with
oral cancer with a plan
for awake nasal
fiberoptic intubation as
an airway management
technique to deal with
the difficult airway
situation in these
patients. This study
was carried out at the
National Cancer
Institute– Cairo
University. Group D1:
Received an infusion
of 1 μcg/kg
dexmedetomidine.
Group D2: Received
an infusion of 2
μcg/kg
dexmedetomidine.
Group DF: Received
an infusion of 1
μcg/kg

insignificant (14–
16/min, P = 0.328).
Patients of Group D had
an acceptable level of
sedation (OAA/S score:
20 to 17 with greater
comfort and satisfaction
(VAS: 40–60).
*All the patients of both
groups maintained
arterial SpO within the
satisfactory level (98%–
99%) during the study
period and the changes
were statistically
insignificant (P = 0.321).
Increasing the dose of
dexmedetomidine
resulted in a significant
increase in airway
obstruction in group D2
(with P = 0.01).
In regards to
hemodynamic
parameters (systolic and
diastolic blood pressure
and HR), all groups were
similar in hemodynamic
values at all-time points
with no interaction
between them (P>0.05).

Group DF resulted
in more patients with
no limb movement
throughout the
procedure (13
patients).
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dexmedetomidine
added to 1 μcg/kg
fentanyl.

Eldemrdash A,
Gamaledeen N,
Zaher Z, Salem
AA. (2017) Level
1 Quality A

Baiju B, G G, K
P, Antony J,
Jayaprakash R.
(2020) Level 1
Quality B

Double blinded
randomized
prospective study was
conducted among 60
patients, aged 20 - 40
years in Aswan
University Hospital,
MP grade III and IV
and TMD < 6.5 cm
were of both sex,
belonging to ASA I
and II, and posted for
elective abdominal
surgeries,
maxillofacial
surgeries. undergoing
AFOI were made into
two groups, group D
Dexmedetomidine 1
mcg/kg, and group F
Fentanyl 2 µg/kg, both
drugs was diluted with
50 ml saline to be
infused over 10
minutes.
Prospective
randomized doubleblind study was done
on 40 patients aged
20–65 years belonging
to ASA Grades 1, 2,
and 3 scheduled for
elective surgeries and
planned for AFOI at a
hospital in central
Kerala. Two groups of

Best RSS was achieved
in Group D (3 ± 0.371)
(P < 0.0001)
Cough score ≤ 2
achieved in 25 out of 30
patients in Group D (P <
0.0001).
Post-intubation score
(Score 1) was found in
24 patients of Group D
(P < 0.0001). 28 patients
of Group D were able to
maintain SpO2 (≥95%)
(P < 0.0001)

Significant increase
in HR (77.767 ±
10.562 beats/min) in
Group F (P <
0.0001). Rise in
MAP in group F
(92-118) (P <
0.0001).

There was no significant
difference in HR,
systolic blood pressure,
diastolic blood pressure,
mean arterial blood
pressure and oxygen
saturation between the
two groups at any point
of time during the study
period (P>0.05).

The mean time of
intubation in the
fentanyl group was
14.10 ± 1.861 min
and in the
dexmedetomidine
group was 11.25 ±
1.333 min
(P<0.001).
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Mondal S, Ghosh
S, Bhattacharya S,
Choudhury B,
Mallick S, Prasad
A. (2015) Level 1
Quality B

patients with 20
patients in each group
were studied for a
period of 2 years. One
group received
fentanyl 2 mcg/kg
infusion over 10 min.
The other group
received
dexmedetomidine 1
mcg/kg infusion over
10 min.
This randomized
double-blind
prospective study was
conducted on a total of
60 patients scheduled
for elective
laparotomies, ASA I
and II. Two groups:
Group D received
dexmedetomidine 1
mcg/kg and Group F
received fentanyl 2
mcg/kg over 10 min.
Patients in both groups
received
glycopyrrolate 0.2 mg
intravenous,
nebulization with 2%
lidocaine 4 ml over 20
min and 10% lidocaine
spray before
undergoing AFOI.

The mean time to
sedation in the fentanyl
group was 7.750 ± 1.499
min and in the
dexmedetomidine group
was 5.250 ± 0.952 min
(P<0.001).

Cough score ≤2 in 30
patients in Group D, but
only in 3 out of 30
patients in Group F (P <
0.0001).
Better post-intubation
score (Score 1) was
found in 24 patients of
Group D (P < 0.0001).
Higher RSS was
achieved in Group D (3
± 0.371) (P < 0.0001).
26 patients of Group D
were able to maintain
SpO (≥95%) (P <
0.0001).
The post-intubation HR
(75 ± 6.48 beats/min)
decreased significantly
in comparison with
baseline value (77.466 ±
5.75 beats/min) in Group
D (P value 0.005).

25 patients in Group
F suffered from
significant
desaturation (SpO
≤94%).
Group F rise of
MAP was
statistically
significant (P <
0.0001).
Significant increase
in HR in the postintubation period
(113 ± 16.482
beats/min) in
comparison with the
baseline value
(77.767 ± 10.562
beats/min) in Group
F (P <0.0001).
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Hassani V,
Farhadi M,
Mohseni M, et al.
(2018) Level 1
Quality B

In this randomized
clinical trial, 52
patients patients
between 20-60 years
old with ASA I-II
undergoing elective
surgery under general
anesthesia with awake
fiberoptic intubation at
Rasul Akram Hospital,
Tehran, Iran. Group D
(n=26) received
dexmedetomidine 1
mcg/kg in 10 minutes
and then 0.5 mcg/kg/h.
Group F (n=26)
received fentanyl 2
mcg/kg and midazolam
1 mg IV.
Yousuf A, Ahad
This prospective,
B, Mir A, Mir A,
randomized study was
Wani J, Hussain
conducted on a total of
S. (2017)
sixty patients of the
Level 1 Quality A ASA I and II of either
sex, in the age group
of 18–60 years having
predicted difficult
intubation undergoing
elective surgeries.
After premedication
and topicalization of
airways,
dexmedetomidine
group (Group D, n =
30) received
dexmedetomidine 1
μg/kg over 10 min and
midazolam–fentanyl
group (Group F, n =
30) received fentanyl 2
μg/kg plus midazolam
0.02 mg/kg over 10
min.

Lower heart rate after
intubation (p=0.008) and
higher SpO2 before
sedation (p<0.001) and
after intubation (p=0.02)
were observed in Group
D.

Group F had
significantly more
cases with no
reaction during
bronchoscopy
(p=0.02).

*Both groups had
comparable RSS and
tolerance during
intubation.

HR of Group D at
postintubation was 87.33
± 9.14 (P < 0.0001).
The mean SBP of Group
D at postintubation was
127.37 ± 7.568.
Mean DBP of Group I at
postintubation was 84.00
± 5.705
The mean RSS in Group
D was 3.13 ± 0.937.
27 patients had a
favorable cough score of
≤2.
22 patients in Group D
had a favorable Post
intubation score.
*The comparison
between the two groups
of post intubation HR,
mean SBP, DBP,
desaturation, cough
score, and post
intubation was

HR mean for Group
F at postintubation
98.40 ± 4.91 with (P
< 0.0001).
Mean RSS score for
Group F was 3.16 ±
0.949
The mean SBP of
Group F was 133.2 ±
6.96.
13 patients in Group
F had desaturation
(SpO2 <95%) with P
= 0.024.
4 patients had a
favorable cough
score of ≤2.
5 patients in Group
D had a favorable
Post intubation
score.
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significant (P<0.05)
favoring
dexmedetomidine.

Liu HH, Zhou T,
Wei JQ, Ma WH.
(2015)
Level 1 Quality A

Jafari A,
Kamranmanesh
M,
Aghamohammadi
H, Gharaei B,
Solhpour A
(2020) Level 1
Quality B

RCT. 90 adult patients
with an American
Society of
Anesthesiologists
classification of grade
I‑II underwent a
modified AFOI
procedure following
airway evaluation.
Rem group vs Dex
Group. Rem group
received a loading
dose of 0.75 µg/kg
infused at 0.15
µg/kg/min over 5 min,
followed by a
continuous infu- sion
of 0.1 µg/kg/min.
Patients in the Dex
group received a
loading dose of 1
µg/kg infused over 10
min, followed by a
continuous infusion of
0.3 µg/kg/h.
60 adult patients
between 30 and 55
years old of ASA I &
II, with Mallampati
score I & II who were
undergoing elective
urologic surgery.
allocated into two
equal groups (n = 30)
to receive either a
loading dose of
dexmedetomidine (1
mg/kg) over 10 min,

The mean time to
achieve sedation with
Dex, was 673.1 sec.

The mean time to
achieve sedation
with Rem was 531.2.

*HR and MAP at five
points no significant
differences between
groups (P>0.05).
*NO statistically
significant differences
were observed in the
sedation scale,
intubation times and
patient reactions when
comparing the two
groups (P>0.05).

7 patients had no cough
in dexmedetomidine
group comparing 21
patients in alfentanil
group (p < 0.0001).
HR and MAP decreased
significantly the end of
drug infusion (RSS ≥3),
dexmedetomidine group
(p = 0.001).

Time taken to
achieve sedation,
endoscopy time,
intubation time in
the alfentanil group
(p<0.001).
Limb movement and
cough more
suppressed among
the alfentanil group
(p < 0.0001).
Alfentanil provided
better patient
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Kumar A, Verma
S, Tiwari T,
Dhasmana S,
Singh V, Singh G.
(2019) Level 1
Quality A

followed by 0.5
mg/kg/h infusion or
alfentanil a loading
dose (20 mg/kg) over
60-90s and then
repeated 10 mg/kg
every 1-2 min over 1020s to reach Ramsay
Sedation Scale (RSS)
≥3.
RCT-Randomized,
double-blind,
comparative study was
conducted in 72
cooperative patients
aged 15–45 years of
either sex ASA I and
II with anticipated
difficult airway
(mouth opening <2
cm, thyromental
distance <6.5 cm, and
Mallampati Class III
and IV) posted for
elective surgical
procedure. Two
Groups: Group I
(dexmedetomidine 1
μg/kg + ketamine 20
mg) or Group II
(dexmedetomidine 1
μg/kg + ketamine 40
mg) of 36 patients
using computergenerated random
table.

satisfaction (p <
0.007).
{atients’ tolerance
and cooperation
during and
immediately after
intubation were
higher in the
alfentanil group (p <
0.0001).
There was a significant
Patients of Group II
difference in mean HR
were deeply sedated
in comparison to
and showed better
baseline values in Group tolerance to
I at all points (P < 0.001) intubation (P <
except at 2 min (P =
0.001).
0.147).
Cough was less
Group I HR variations
severe in terms of
(ranged between 0.09%
grading described
and 9.81%).
before in Group II (P
MAP in Group I showed = 0.023).
a declining trend in
Significantly higher
comparison to the
proportion of
baseline values at all
patients of Group II
times of observation (P
was easiest to
< 0.001).
intubate (P = 0.041).
Group II patients
Level of discomfort was showed less
more and statistically
variation from their
significant (P < 0.001) in baseline values in
Group I.
terms of HR (ranged
between 0.73% and
4.75%)
MAP in Group II
showed an uprising
trend in comparison
to baseline values at
all times (P < 0.001,
at 10 min after
intubation P =
0.033)
Group II patients
showed less
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Kaur B, Garg A,
Kumar P, Yadav
DN (2019) Level
1 Quality B

Blind RCT of 100 total
patients (ASA I and
ASA II), study was
conducted in
Department of
Anesthesia and
intensive care,
Government Medical
College, Rajindra
Hospital, Patiala: Two
experimental groups
50 patient in each
experimental group.
Both received IV
dexmedetomidine
1µg/kg over 10 mins.
Group-DK patients
received ketamine
0.25 mg/kg IV and
Group-DP patients
received propofol
1mg/kg IV.

El Mourad MB,
Elghamry MR,
Mansour RF,
Afandy ME.
Comparison of
intravenous
dexmedetomidinepropofol versus
ketofol for
sedation during
awake fiberoptic

Double-blind RCT of
80 patients of either
gender, aged 18 - 60
years, ASA I-III, and
difficult airway
intubation due to
laryngeal mass who
were candidates for
laryngeal mass biopsy
under general
anesthesia. Two

There is better
hemodynamic stability
pertaining to HR, SBP,
DBP, MAP while
maintaining oxygen
saturation in
dexmedetomidine
(1µg/kg) plus ketamine
(0.25mg/kg) group.
Higher SpO2 levels
where maintained in the
DK group during
fiberscope insertion and
endotracheal intubation
(p<0.05).
Patients were more
comfortable in group
DK as compare to group
DP during fiberscope
and intubation (p<0.05).
Better patient tolerance
was observed in group
DK (p<0.05).
Patients in group D had
statistically significant
lower MAP and HR after
the loading dose till five
minutes after intubation
(from T1 to T6) (P =
0.000).

*No statistically
significant difference in

variation from their
baseline values in
terms of MAP
(ranged between 0%
and 3.97%)
There was lesser
recall of fiberscopy
procedure in Group
II (P < 0.001),
Significant decrease
in MAP during
fiberscope insertion
and ETT insertion in
group DP (P value=
<0.001) as compare
to group DK.

Time to reach RSS ≥
3 and intubation
time were
significantly shorter
(P = 0.000*) with
fewer number of
intubation attempts
in the K group.
The number of
patients that needed
rescue doses of
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intubation: A
prospective,
randomized study.
2019

groups the
dexmedetomidinepropofol (group D; n =
40) or ketofol (group
K; n = 40).

cough scores were
propofol was also
observed between the
significantly less in
two groups (P = 0.611).
group K (P = 0.035).
No hypoxic episodes
(SpO2 < 92%) or apneic
attacks were noted.
Patients’ satisfaction
levels were similar in the
two groups (P = 0.687).
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Appendix C: IRB Exemption Letter
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Appendix D: QI Project Consent Form
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Appendix E: QI Project Survey

Pretest and Posttest Questionnaire:
Management of Awake Fiberoptic Intubation
INTRODUCTION
The primary aim of this QI project is to improve the knowledge of utilizing
dexmedetomidine for awake fiber optic intubation (AFOI) to optimize sedation, maximize
patient comfort while maintaining spontaneous ventilation.
Please answer the question below to the best of your ability. The questions are in multiple
choice format. These questions are meant to measure knowledge and perceptions on
identification, referral, management, and patient education on the use of dexmedetomidine for
AFOI.
PERSONAL INFORMATION
1. Gender: Male

Female

Other

2. Age: ______
3. Ethnicity: Latino/a Caucasian

African American

Asian Other

4. Position/Title: SRNA CRNA MD/DO
5. Years of experience:

Less than 1 year

1 to 5

6 to 10

QUESTIONNAIRE
1. What group or groups of medication do you use for AFOI?
a. Opioids
b. Benzodiazepines
c. Propofol
d. Ketamine
e. Dexmedetomidine

more than 10 years
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f. Other
2. If an opioid is utilized, which one do you prefer?
a. Fentanyl
b. Remifentanil
c. Sufentantil
d. Alfentanil
e. Other
3. Please select dexmedetomidine mechanism of action?
a. α2 adrenergic antagonist, sedative properties, nonanalgesic, and anxiolytic,
antisialogogue, with clinical significant respiratory depression.
b. α2 adrenergic agonist, sedative properties, analgesic, and anxiolytic,
antisialogogue, with respiratory depression.
c. α2 adrenergic agonist, sedative properties, analgesic, and anxiolytic,
antisialogogue, with nonclinical significant respiratory depression.
d. α2 adrenergic antagonist, sedative properties, analgesic, and anxiolytic,
antisialogogue, with respiratory depression.
4. Where does dexmedetomidine work in the brain?
a. Brain stem
b. Locus coeruleus
c. Amygdala
d. Hypothalamus
5. The most common side effects of dexmedetomidine are?
a. Low or High blood Pressure, Bradycardia, dry mouth, hyperglycemia.
b. Low or High blood pressure, bradycardia, dry mouth, hypoglycemia.
c. Low blood pressure, bradycardia, dry mouth, hyperglycemia.
d. High Blood pressure, bradycardia, dry mouth, hypoglycemia.
6. According to multiple randomized control studies which sedative provides optimum
sedation for AFOI while maintaining spontaneous ventilation?
a. Ketamine
b. Propofol
c. Etomidate
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d. Dexmedetomidine
7. Which drug according to a recent randomized control trial provides optimum
conditions for AFOI?
a. Ketamine
b. Etomidate
c. Propofol
d. Alfentanil
8. Alfentanil mechanism of action?
a. Opioid antagonist at the delta receptor, low toxicity, short duration, blunts airway
reflex, does not cause bradycardia and hypotension.
b. Opioid agonist at the mu receptor, low toxicity, short duration, blunts airway
reflex, does not cause bradycardia and hypotension.
c. Opioid agonist at the mu receptor, low toxicity, short duration, blunts airway
reflex, does not cause bradycardia and hypotension.
d. Opioid agonist at the delta receptor, low toxicity, short duration, blunts airway
reflex, does cause bradycardia and hypotension.
9. What is the best initial dosage of dexmedetomidine and alfentanil for AFOI?
a.

Dexmedetomidine 1mcg/kg over 10 minutes/Alfentanil 20mcg/kg over 60-90s.

b. Dexmedetomidine 1mcg/kg over 10 minutes/Alfentanil 40mcg/kg over 60-90s.
c. Dexmedetomidine 1mcg/kg over 10 minutes/Alfentanil 10mcg/kg over 60-90s.
d. Dexmedetomidine 1mcg/kg over 10 minutes/Alfentanil 30mcg/kg over 60-90s.
10. How likely are you to utilize dexmedetomidine and alfentanil for awake fiber optic
intubation?
a. Extremely likely
b. Somewhat likely
c. Neither likely or unlikely
d. Somewhat unlikely
e. Extremely Unlikely
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Appendix F: Educational Module

